SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$344M
Q4 2023
Positions
31
Filings on Record
15
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Artia Global Partners LP reported $344M in U.S.-listed holdings across 31 positions for Q4 2023.

The portfolio is heavily concentrated: NVO alone accounts for 21.7% of reported value.

Compared with Q3 2023, the fund opened 12 new positions and exited 8.

Portfolio Metrics

Turnover
+21.4%
vs prior filed quarter
Top-10 Concentration
+66.2%
share of reported value
Largest Position
+21.7%
Novo Nordisk A S
New / Exited
12 / 8
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 43.4%ADR: 30.0%Other: 26.6%
  • Common Stock · 43.4% · $149M
  • ADR · 30.0% · $103M
  • Other · 26.6% · $91M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CYTOKINETICS INCNEW+404.9K404.9K+$34M$34M
CYTOKINETICS INCNEW+400.5K400.5K+$33M$33M
ELI LILLY & CONEW+40.0K40.0K+$23M$23M
CYTKCYTOKINETICS INCNEW+32.1K32.1K+$3M$3M
VRNAVERONA PHARMA PLCNEW+130.8K130.8K+$3M$3M
IM8NINSMED INCNEW+74.9K74.9K+$2M$2M
OCULOCULAR THERAPEUTIX INCNEW+440.0K440.0K+$2M$2M
EYPTEYEPOINT PHARMACEUTICALS INCNEW+50.0K50.0K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

27 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NVONOVO-NORDISK A Shistory →ADR21.71%$75M721.5K
2LLYELI LILLY & COhistory →COM15.70%$54M92.6K
3MRKMERCK & CO INChistory →COM10.44%$36M329.2K
4ABBVABBVIE INChistory →COM4.09%$14M90.8K
5ARGXARGENX SEhistory →SPONSORED ADR3.79%$13M34.2K
6AZNNASTRAZENECA PLChistory →SPONSORED ADR3.74%$13M190.8K
7VKTXVIKING THERAPEUTICS INChistory →COM2.08%$7M383.6K
8AXSMAXSOME THERAPEUTICS INChistory →COM2.03%$7M87.8K
9NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.72%$6M45.0K
10ITCIEURINTRA-CELLULAR THERAPIES INCCOM0.87%$3M41.6K
11BMRNBIOMARIN PHARMACEUTICAL INCCOM0.81%$3M28.9K
12CYTKCYTOKINETICS INCCOM NEW0.78%$3M32.1K
13VRNAVERONA PHARMA PLCSPONSORED ADS0.76%$3M130.8K
14PTGXPROTAGONIST THERAPEUTICS INCCOM0.75%$3M112.3K
15PCVXVAXCYTE INCCOM0.70%$2M38.6K
16IM8NINSMED INCCOM PAR $.010.68%$2M74.9K
17OCULOCULAR THERAPEUTIX INCCOM0.57%$2M440.0K
18PLRXPLIANT THERAPEUTICS INCCOM0.53%$2M100.0K
19CHARLES RIV LABS INTL INCCOM0.47%$2M6.9K
20EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.34%$1M50.0K
21WATWATERS CORPCOM0.27%$936,6592.8K
22IMVTIMMUNOVANT INCCOM0.26%$901,45621.4K
23RAPT THERAPEUTICS INCCOM0.14%$488,00419.6K
24BMEABIOMEA FUSION INCCOM0.11%$369,56325.5K
25APGEAPOGEE THERAPEUTICS INCCOM0.08%$290,04510.4K
262JQGRITSTONE BIO INCCOM0.06%$194,14795.2K
27TYRATYRA BIOSCIENCES INCCOM0.04%$142,00410.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.